Aspirin, naproxen, sulindac acid, amino salicylic acid, and celecoxib are NSAIDs that should be considered for use in combination with EZH2 inhibitors for KRAS-driven NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.